

Special Section on Phosphoproteomic Analysis of G Protein-Coupled Pathways - Axelrod
Symposium—Minireview

Phosphoproteomics-Based Characterization of Prostaglandin E₂ Signaling in T Cells

Anna Mari Lone and Kjetil Taskén

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital (A.M.L., K.T.) and Institute for Clinical Medicine, University of Oslo, Oslo, Norway (K.T.)

Received October 1, 2020; accepted March 1, 2021

ABSTRACT

Prostaglandin E₂ (PGE₂) is a key lipid mediator in health and disease and serves as a crucial link between the immune response and cancer. With the advent of cancer therapies targeting PGE₂ signaling pathways at different levels, there has been increased interest in mapping and understanding the complex and interconnected signaling pathways arising from the four distinct PGE₂ receptors. Here, we review phosphoproteomics studies that have investigated different aspects of PGE₂ signaling in T cells. These studies have elucidated PGE₂'s regulatory effect on T cell receptor signaling and T cell function, the key role of protein kinase A in many PGE₂ signaling

pathways, the temporal regulation of PGE₂ signaling, differences in PGE₂ signaling between different T cell subtypes, and finally, the crosstalk between PGE₂ signaling pathways elicited by the four distinct PGE₂ receptors present in T cells.

SIGNIFICANCE STATEMENT

Through the reviewed studies, we now have a much better understanding of PGE₂'s signaling mechanisms and functional roles in T cells, as well as a solid platform for targeted and functional studies of specific PGE₂-triggered pathways in T cells.

Introduction

Prostaglandin E₂ in T Cell Signaling and Function

The lipid mediator prostaglandin E₂ (PGE₂) is the most abundant prostanoid in the human body and regulates key processes in normal physiology and disease, including in cancer (O'Callaghan and Houston, 2015) and in inflammatory conditions (Brudvik and Taskén, 2012). In particular, PGE₂ has received attention for the dual role it plays in the immune system as both a driver of acute inflammation and as an immunosuppressive mediator that contributes in the resolution phase of inflammation. PGE₂ thus constitutes an important link between the inflammatory response and cancer (Nakanishi and Rosenberg, 2013). PGE₂ is elevated in several different cancer types, including colon, lung, and breast cancer, and is often associated with a poor prognosis (Wang and DuBois, 2013).

In the tumor microenvironment, PGE₂ is produced by tumor cells, monocytes, and induced Tregs (Mahic et al., 2006; Scott et al., 2013) through an enzymatic cascade involving cyclooxygenase (COX) activity and prostaglandin E synthase (Tong et al., 2018). In this cancer setting, PGE₂ has established roles in promoting cancer cell proliferation, survival, migration, and invasion, as well as in angiogenesis (Lone and Taskén, 2013). Aside from direct effects on tumor cells, PGE₂ acts on a number of the other cell types present in the tumor microenvironment, ultimately contributing to the formation of an immunosuppressive tumor microenvironment (Wang and DuBois, 2013). For instance, PGE₂ inhibits natural killer cell and dendritic cell function (De Keijzer et al., 2013) and promotes a shift from antitumor M1 to tumor-promoting M2-type macrophages (De Keijzer et al., 2013; Wang and DuBois, 2013, 2018). In T cells, PGE₂ has a number of distinct effects on apoptosis, activation-induced cell death, differentiation, and T cell function, including T cell receptor (TCR) signaling, proliferation, cytotoxicity, and cytokine production (Sreeramkumar et al., 2012; Lone and Taskén, 2013).

PGE₂ mediates these effects on T cell function through four distinct G protein-coupled receptors (GPCRs), termed EP_{1–4}, all of which are present on T cells. The EP receptors initiate

Our work has been supported by the Norwegian Cancer Society [Grants 182794 and 215850], The Regional Health Authority for South-Eastern Norway [Grant 2017119], the Research Council of Norway [Grants 294916 and 315538], and Stiftelsen Kristian Gerhard Jebsen [Grants SKGJ-MED-09 and SKGJ-MED-19].

The authors declare no conflicts of interest.

<https://doi.org/10.1124/molpharm.120.000170>

ABBREVIATIONS: COX, cyclooxygenase EP Receptor E-Prostanoid Receptor; GPCR, G protein-coupled receptor; MS, mass spectrometry; PDE, phosphodiesterase; PFP, Predict Functional Phosphosites; PGE₂, prostaglandin E₂; PTM, post-translational modifications; TCR, T cell receptor; Treg, regulatory T cell.

distinct and shared downstream pathways (Woodward et al., 2011; Sreeramkumar et al., 2012; O'Callaghan and Houston, 2015; Lone et al., 2021). The EP₁ receptor signals mainly through Gα_q, which activates PLC, Ca²⁺, and PKC signaling. The EP₂ and EP₄ receptors both couple to the stimulatory G protein Gα_s, which signals through cAMP elevation and PKA activation. In addition, EP₄ can also couple to the inhibitory G protein Gα_i and thus activate additional signaling pathways (Fujino and Regan, 2006; Yokoyama et al., 2013). EP₃ has several different isoforms that can couple to various G proteins, but the main signaling pathway is thought to occur through Gα_i. In addition to the canonical Gα signaling pathways, the EP receptors also signal through Gβγ subunits, in particular in conjunction with Gα_i signaling (Fujino et al., 2002; Fujino and Regan, 2006; Yokoyama et al., 2013). Further, G protein-independent signaling pathways, such as through β-arrestin, have also been shown to occur downstream of some of the EP receptors (Buchanan et al., 2006; DeWire et al., 2007; Chun et al., 2009; Kim et al., 2010; Luttrell and Miller, 2013; Tan et al., 2017).

There has been significant interest in targeting some of these PGE₂ signaling pathways in cancer. For instance, the use of COX1/2 inhibitors, which block the rate-limiting step in PGE₂ biosynthesis, reduces colorectal cancer incidence (Rothwell et al., 2010) and improves survival if given after the initial diagnosis (Bains et al., 2016). PGE₂ receptors EP₁, EP₂, and EP₄ have also been targeted with antagonists, and there is significant interest in combining EP₄ antagonists with immunotherapy (Table 1). Previously, synergy between immunotherapy and other ways of targeting PGE₂ has been demonstrated. For instance, COX inhibitors enhance the effect of immune checkpoint blockade (Zelenay et al., 2015), and a peptide that blocks an inhibitory PGE₂ signaling pathway augments the antitumor efficacy of chimeric antigen receptor (CAR) T cells (Newick et al., 2016). Given the interest in targeting PGE₂ signaling pathways and their multifaceted roles in health and disease, it is important to have a thorough understanding of pathways, networks, and functions regulated by PGE₂ in different cell types in health and disease. Much of what is known about PGE₂ signaling has been discovered through classic biochemical signaling studies, which have identified and characterized specific PGE₂ signaling pathways and functional output in many different cell types, including in T cells (Vang et al., 2001; Carlson et al., 2006; Mahic et al., 2006; Ruppelt et al., 2007; Stokka et al., 2009; Mosenden et al., 2011; Brudvik et al., 2012; Brudvik and Taskén, 2012; Lone and Taskén, 2013). In recent years, however, large-scale proteomics studies have contributed to a more global view of PGE₂ signaling networks in different cell types, and this review article will focus on such studies in T cells.

Phosphoproteomics and Its Application to Signaling Studies

Post-translational modifications (PTMs) are covalent changes to proteins after translation and include a variety of modifications, including, among others, ubiquitination, acetylation, methylation, proteolysis, and phosphorylation (Walsh et al., 2005). These PTMs constitute an important mechanism for regulating protein localization, stability, protein-protein interactions, function, and activity (Mnatsakanyan et al., 2018).

TABLE 1

Current clinical trials with EP₄ antagonists.

This table gives an overview of current clinical trials with EP₄ antagonists in cancer. To identify clinical trials, a search was performed on clinicaltrials.gov with the keyword "Prostaglandin E2," selecting for interventional studies and condition = cancer/neoplasm/tumor. In addition, searches were also performed with the names of all EP₄ antagonists listed in the database <https://www.guidetopharmacology.org>, as well as EP₄ antagonists found by searching the NCI Drug Dictionary: <https://www.cancer.gov/publications/dictionaries/cancer-drug>. Abbreviations: NCI - National Cancer Institute, MSS - microsatellite stable, PD-1 - Programmed death 1, PD-L1 - Programmed Death 1 Ligand 1, NSCLC - Non small-cell lung cancer, DMARD - disease modifying antirheumatic drugs

Trial Number	Title	Conditions	EP ₄ Antagonist	Combination with	Status	Phase
NCT043444795	Phase 1a/1b study of TPST-1495 alone and with Pembrolizumab in subjects with solid tumors	Solid tumor, microsatellite stable colorectal cancer, adenocarcinoma of the lung, squamous cell carcinoma of head and neck, bladder cancer, triple-negative breast cancer, gastric cancer	TPST-1495	Pembrolizumab	Recruiting	1
NCT03658772	Grapiprant and Pembrolizumab in patients with advanced or progressive MSS colorectal cancer	Microsatellite stable colorectal cancer	Grapiprant	Pembrolizumab	Recruiting	1
NCT03696212	Grapiprant (ARY-007) and Pembrolizumab in patients with advanced or metastatic post-PD-1/L1 NSCLC adenocarcinoma	Non-small-cell lung cancer adenocarcinoma	Grapiprant and	Pembrolizumab	Recruiting	1, 2
NCT02538432	Phase 2 trial of EP ₄ receptor antagonist AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors	Prostate cancer non-small-cell lung cancer breast cancer	RQ-00000007	Gemcitabine	Withdrawn	2
NCT03163966	A study of the EP ₄ antagonist CR6086 in combination with methotrexate, in DMARD-naïve patients with early rheumatoid arthritis	Rheumatoid arthritis, DMARD-naïve, and early disease patients	CR6086	Methotrexate	Unknown	2
NCT00957983	EP ₄ receptor antagonism and prostaglandin E ₂ in a human headache model	Headache, migraine	BGC20-1531		Completed	1, 2

The best-characterized PTM is protein phosphorylation, which is a rapid and reversible modification in which phosphate groups are added to specific amino acid residues. Serine, threonine, or tyrosine residues can be phosphorylated, and the extent of phosphorylation is tightly regulated by kinases and phosphatases, which add and remove, respectively, phosphate groups at specific sites on proteins. As much as 30% of cellular proteins are thought to be phosphorylated (Cohen, 2000), and with more than 500 kinases and 100 phosphatases, approximately 3% of the human proteome is thought to be dedicated to the regulation of phosphorylation (Manning et al., 2002; Alonso et al., 2004). Phosphorylation events can change the conformation or binding properties of a protein to yield changes in enzymatic activity, subcellular localization, or stability (von Stechow et al., 2015; Álvarez-Salamero et al., 2017). Phosphorylation plays an important role in signal transduction, which in turn regulates key cellular processes such as cell division, proliferation, migration, differentiation, and survival (Álvarez-Salamero et al., 2017). Dysregulation of phosphorylation is frequently observed in cancer, metabolic disorders, and immune conditions (Lahiry et al., 2010; Cohen, 2014; Needham et al., 2019).

Until recently, phosphorylation events were largely studied individually using biochemical methods. The advent of mass spectrometry (MS) methods has enabled the assessment of phosphorylation levels on a more global level in a cell. These techniques began picking up speed a little more than a decade ago, and since then, there have been significant advances in techniques and instrumentation that allow for the characterization of ever-increasing numbers of phosphosites in a given experiment (Lemeer and Heck, 2009; Macek et al., 2009; Grimsrud et al., 2010). One of the main technical advances is in the instrumentation, in which the ever-increasing acquisition speed and sensitivity of mass spectrometers have contributed to increased depth and throughput of proteomics studies (von Stechow et al., 2015; Riley and Coon, 2016). Further, sample fractionation methods have contributed toward deeper coverage of the phosphoproteome by reducing the complexity of the MS samples, as have developments in phosphoprotein enrichment strategies that isolate the phosphoproteome prior to MS analysis, thus compensating for the relatively low abundance of phosphopeptides compared with unmodified peptides (Riley and Coon, 2016). Data acquisition methods such as data-independent analysis are also beginning to remedy the challenge of the wide dynamic range of the phosphoproteome, which is caused by the substoichiometric nature of phosphorylation (Chapman et al., 2014; Riley and Coon, 2016; Needham et al., 2019). Thanks to these advances, current studies routinely characterize tens of thousands of phosphosites in a single experiment (Riley and Coon, 2016).

In immunology, proteomics is coming to play an important role, for instance, in the study of protein expression levels, subcellular localization, secretion, and interaction, and for studying post-translational modifications (Nyman et al., 2017). In particular, phosphoproteomics studies are beginning to provide a more global picture of the phosphorylation landscapes in immune cells. In T cells, phosphoproteomics has been used to study a wide variety of signaling processes, including TCR, interleukin 2 (IL2), and chemokine signaling, as well as signaling in various pathophysiological conditions, such as human immunodeficiency virus infection and various T lymphocyte-mediated diseases (Álvarez-Salamero et al., 2017;

Helou and Salomon, 2015). In the future, it might also be interesting to use phosphoproteomics to assess the effect of promising new cancer therapies such as immune checkpoint inhibitors on protein phosphorylation patterns in T cells. A handful of studies have also begun to use phosphoproteomics to shed light on PGE₂ signaling in T cells, and this will be the focus of this review.

Phosphoproteomics Studies of PGE₂ Signaling in T Cells

In the past decade, mass spectrometry-based phosphoproteomics studies have contributed to a much broader and more detailed overview of PGE₂ signaling in T cells (Table 2). A common factor in these studies has been an interest in characterizing entire signaling networks downstream of stimulation with PGE₂ and how these might affect T cell function. Although some studies have focused specifically on PKA signaling networks, which are known to be major contributors to PGE₂ signaling output (Giansanti et al., 2013), other studies have looked more broadly at all PGE₂-initiated signaling events. Below, we will review common and specific themes and insights from these studies.

PKA Signaling and Interaction with TCR Signaling

One of the main biologic insights resulting from these studies is that PKA phosphorylation plays a central role in the signaling downstream of PGE₂. Previous biochemical and cellular studies had implicated PKA in specific signaling pathways downstream of PGE₂, and in particular had identified a PKA-mediated inhibitory pathway that proceeds through EP₂/EP₄, cAMP/PKA, and nonreceptor tyrosine kinases C-terminal Src kinase (Csk) and lymphocyte-specific protein tyrosine kinase (Lck), ultimately leading to inhibition of TCR signaling, which is crucial for T cell function (Vang et al., 2001). A combined phosphoproteomics and phosphoflow cytometry study on PGE₂ signaling in primary lymphocytes demonstrated the significance of this pathway in T cells. First, the phosphoproteomics study revealed that PGE₂ regulated a number of phosphosites on proteins found downstream of TCR, such as CARD11, PLCG1, WIPF1, GRAP2, NFATC2, FYB1, and NCK1 (Fig. 1; Table 3). Phosphoflow cytometry, which uses fluorophore-labeled phosphospecific antibodies to assess intracellular phosphorylation levels in a high-throughput manner by flow cytometry, was then used to follow up on these findings. The phosphoflow cytometry study demonstrated that the level of basal signaling through the inhibitory pathway in specific cell types sets the threshold for TCR signaling in primary T cells (Oberprieler et al., 2010), with CD8CD45RO cells exhibiting particularly high constitutive signaling through the inhibitory pathway and consequently low TCR signaling. Exogenously added PGE₂ had a similar dampening effect on TCR signaling, regardless of the basal signaling through PKA. To follow up on these insights, a further, more focused study was undertaken that demonstrated that this mechanism is also active in patients with patients, in which high levels of circulating PGE₂ limits TCR and interleukin 2 (IL2) signaling in peripheral T cells (Moltu et al., 2017). This example highlights how phosphoproteomics and phosphoflow

TABLE 2
List of phosphoproteomics studies of PGE₂ signaling
 The table gives an overview of the studies discussed in this review article. In addition to the four phosphoproteomics studies of PGE₂ signaling in T cell, two related articles have also been included. Abbreviations: PMID - PubMed Identifier, Ti4+ - titanium (IV) ion, IMAC - immobilized metal affinity chromatography.

Study	Cell Type	Labeling	Enrichment	Data and Pathway Analysis Approaches	Notes
Oberprieler et al. (2010). High-resolution mapping of prostaglandin E ₂ -dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. PMID: 20558615	Primary CD3+	Stable isotope dimethyl labeling		PhosphoSitePlus, NetworkKIN, Scansite, Phosida, IceLogo	Combined with phosphoflow
Giansanti et al. (2013). Interrogating cAMP-dependent kinase signaling in Jurkat T cells via a protein kinase A targeted immunoprecipitation phosphoproteomics approach. PMID: 23882029	Jurkat	Stable isotope dimethyl labeling	PKA motif antibody enrichment	Ingenuity Pathway Analysis, Cytoscape, STRING, PhosphoSitePlus	
de Graaf et al., 2014. Single-step enrichment by Ti4+-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal Resolution. PMID: 24850871	Jurkat	Label-free		STRING, NetworkKIN, IceLogo, Gene Ontology analysis	
Lone et al., 2021. Systems approach reveals distinct, joint signaling networks of the four PGE ₂ receptors in T Cells	Primary CD4+, CD8+, Tregs	Label-free		NetworkKIN, IceLogo, Phonemes, STRING, PhosphoSitePlus, Predict Functional Phosphosites	Combined with phosphoflow Individual stimulation of 4 PGE ₂ receptors Related study
Gerarduzzi et al. (2014). Quantitative phosphoproteomic analysis of signaling downstream of the prostaglandin E ₂ /G-protein coupled receptor in human synovial fibroblasts: potential antifibrotic networks. PMID: 25223752	Primary synovial fibroblasts	Label-free	PKA motif antibody enrichment	Ingenuity Pathway Analysis	
Belajar et al. (2017). Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells. PMID: 28634298	Jurkat	Label-free		NetPhorest, Predict Functional Phosphosites, STRING, Gene Ontology Analysis	Related study. Combined stimulation with PDE inhibitors and PGE ₂

cytometry can complement more detailed molecular studies, and together characterize both specific pathways as well as the functional impact of these—as for the interaction between the PGE₂ and TCR signaling pathways. It also demonstrates that the combination of phosphoproteomics with phosphoflow cytometry can be a powerful way of achieving both a global overview as well as detailed knowledge about the kinetics, dose dependence, and cell-type specificity of specific regulated events (Oberprieler and Taskén, 2011).

Further evidence for the general importance of PKA in PGE₂ signaling was provided by a targeted phosphoproteomics study, which delved deeper into the importance of PGE₂ as a regulator of PKA signaling (Giansanti et al., 2013). In this study, an antibody specific for the PKA phosphorylation motif ([R/K][R/K/X][pS/pT]) was used to enrich phosphorylated PKA substrates triggered by PGE₂, thus zooming in on this particular signaling pathway, as opposed to the more common nonselective, shotgun phosphoproteomics approaches. Because of the enrichment, relatively few sites were identified (655 peptides, of which 642 had the PKA motif). Interestingly, the overlap with a large-scale Jurkat phosphoproteomics data set was only 0.2%, illustrating the power of targeted approaches in complementing untargeted studies by generating unique information. Stimulation conditions were different in the two studies, so complete overlap would not be expected, but this nonetheless illustrates the fact that, in untargeted studies, less abundant sites may be selected against due to data-dependent acquisition, and a targeted study may thus provide unique access to sites that otherwise would not be detected. These predominantly new phosphosites provide a useful resource of potential PKA substrates in T cells and illustrate how a targeted approach can be useful to gain information on targets of a particular kinase. In addition, based on the basic substrate motif used for enrichment of potential substrates, additional information was gained about PKA motifs in real PKA substrates. In particular, the authors found that small residues are common in the P-1 position, and hydrophobic residues are common in P+1. In addition, they identified some unconventional PKA motifs in which histidine substitutes as a basic residue at position P-3. In other words, this targeted approach was used to both obtain a list of novel potential PKA substrates and gain new information about possible PKA substrate motifs. All in all, the study underlined the importance of PKA in PGE₂ signaling and mapped out the PKA-regulated substrates that are PGE₂-regulated. Further, it showed the potential of zooming in on particular pathways using enrichment-based mass spectrometry methods, which often provide high selectivity and orthogonality relative to shotgun approaches.

A general problem in detecting substrates of the AGC subfamily of kinases, including those of PKA, by phosphoproteomics, is the frequent use of trypsin to digest proteins into peptides detectable by mass spectrometry. Of the studies discussed here, both Oberprieler et al., de Graaf et al., and Lone et al. used trypsin either alone or together with Lys-C. Trypsin cleaves after R/K, and will therefore cleave close to many PKA-targeted phosphosites conforming to the motif RRXS/T. However, PKA substrates still appear to be detected quite efficiently by MS in the trypsin-based studies. For instance, in Lone et al., the sequence motifs of regulated phosphosites show a clear enrichment for R/K in positions -2/-3 for most stimulation condition. In addition, several classic




Fig. 1. PGE₂ signaling regulates phosphorylation of proteins involved in TCR signaling. Phosphosites regulated by PGE₂ in the four different phosphoproteomics studies were queried against proteins included in the GO term “T cell receptor signaling pathway” (gray). TCR signaling proteins (green) have phosphosites regulated by PGE₂ or one of the EP receptor agonists in one or more of the phosphoproteomics studies. Asterisks indicate proteins not included in GO term TCR signaling (GRAP2 = GADS, NCK1) but known to be involved in TCR signaling and regulated in (Oberprieler et al. 2010)

PKA substrates, such as BAD pS118 and CAD pS1406, were detected in the study. The other trypsin-based studies also detected many known PKA substrates.

Phosphodiesterases (PDEs) are enzymes responsible for breaking down cAMP, and they are known to be phosphorylated and regulated by PKA, which was also observed in

several of the studies described here. For instance, PDE3B S442, which is situated in a typical PKA recognition motif, was regulated by EP1 and EP2 agonists in CD8 T cells in one study (Lone et al., 2021). A recent study on PDEs further highlighted the complexity of PGE₂ cAMP-PKA-mediated signaling, the interaction with different PDEs, and the multiple possible

TABLE 3

Proteins from GO term T cell receptor signaling pathway whose phosphorylation is regulated by PGE₂

The table shows proteins contained in GO term T cell receptor signaling pathway that have one or more phosphosites that are regulated by PGE₂ or one of the EP receptor agonists in one or more of the phosphoproteomics studies reviewed here. Commonly used alternative names for the proteins are shown in parenthesis.

TCR Signaling Protein	Oberprieler	Giansanti	de Graaf	Lone	Conditions Regulated in Lone
BRAF					
CARD11 (Carma1)	✓	✓	✓	✓	CD8 EP1, EP2, EP3, EP4, PGE2
CD247 (CD3ζ)			✓	✓	CD8 EP1, EP2, EP3
CD3E			✓	✓	
ELF1			✓	✓	
FYB1 (ADAP)	✓		✓	✓	CD8 EP2, EP4
FYN			✓	✓	CD8 EP2
GATA3			✓	✓	
LCK	✓		✓	✓	CD8 EP2 CD4 EP1, EP2, EP3, EP4, PGE2
LCP2 (SLP76)	✓		✓	✓	CD8 EP2
LIME1			✓	✓	CD8 EP1, EP2, EP3, EP4, PGE2
MAPK1			✓	✓	
PLCG1	✓		✓	✓	CD8 PGE2
PRKD2	✓		✓	✓	CD4 EP4
PTPN22 (LYP)			✓	✓	CD8 EP2
PTPRC (CD45)			✓	✓	CD8 EP2
RFTN1			✓	✓	CD8 EP2
RNF31			✓	✓	
SPN (CD43)	✓		✓	✓	CD8 EP1, EP2, EP3, EP4, PGE2 CD4 EP1, EP2, EP3, EP4, PGE2
TESPA1			✓	✓	CD8 EP2
TRAT1 (TRIM)			✓	✓	
WNK1	✓	✓	✓	✓	CD8 EP2, EP4

roles of cAMP signaling upon PGE₂ stimulation (Beltejar et al., 2017).

Here, the authors demonstrated that inhibition of different groups of PDEs in the presence of PGE₂ resulted in the upregulation of distinct phosphoproteomes and distinct functional compartments, underlining the downstream complexity of PGE₂-mediated cAMP-PKA signaling in T cells.

A more recent study has also underlined the significance of the PKA node in PGE₂ signaling (Lone et al., 2021) and further delineated its importance in signaling deriving from the four different EP receptors. In particular, the study demonstrated the predominance of PKA signaling in both EP₂ and EP₄ receptor signaling using phosphoflow cytometry, with EP₂ demonstrating more intense and longer duration of PKA-mediated signaling. The intensity difference is likely due to EP₄'s secondary coupling to G α_i , whereas the difference in signaling duration may be due to EP₄'s higher susceptibility to internalization and desensitization than EP₂, which is caused by its longer intracellular C-terminal (Nishigaki et al., 1996; Bastepe and Ashby, 1999; Desai et al., 2000). It appears that EP₂ is less able to bind β -arrestins than EP₄ but may bind certain arrestins to some extent (Penn et al., 2001; Chun et al., 2009), either as part of the desensitization process or in the context of G protein-independent signaling, which we incidentally observed a significant amount of in our recent study (Lone et al., 2021). In addition, the phosphoflow part of that study showed some evidence of phosphosites responding in opposite directions upon EP₃ or EP_{2/4} stimulation. This would be expected, since EP₃ is thought to mainly couple to G α_i , reducing intracellular cAMP and PKA signaling, and EP_{2/4} are thought to primarily couple to G α_s , increasing intracellular cAMP and PKA signaling. Some evidence of potentially opposing effects of EP₃ and EP_{2/4} was also observed in the mass spectrometry part of the study, in which EP₂ stimulation resulted in more regulated sites than PGE₂ stimulation, indicating that PGE₂ signaling, which would be expected to occur through all four EP receptors, is not simply additive. In particular, EP₃ signaling may dampen the effects of EP_{2/4} signaling when all receptors are triggered simultaneously. It is interesting that nature has provided such a complex system of four distinct receptors all responding to the same stimulus, and in particular two receptors, EP₂ and EP₄, which both signal primarily through G α_s . Presumably, the crosstalk between the receptors, the difference in signaling intensity and duration (in particular between EP₂ and EP₄), and differences in coupling capabilities between receptors, as well as differences in relative receptor expression between cell types, allow this family of four receptors to provide a more fine-tuned response to PGE₂ stimulus than any one receptor could alone.

Further underlining the importance of PKA in PGE₂ signaling networks, PKA also assumes a key position in the modeled networks deriving from this phosphoproteomics study, both for PGE₂ stimulation of all receptors and for specific stimulation of each EP receptor.

Non-PKA Signaling Nodes and Pathways

Undoubtedly, PKA is a major mediator of PGE₂ signaling, but phosphoproteomics studies have also showcased other important kinase nodes and signaling pathways regulated by PGE₂. In particular, a combined phosphoproteomics and

phosphoflow cytometry study (Oberprieler et al., 2010) implicated kinases such as CamKII and Akt as possible weaker signaling nodes, largely based on kinase predictions. A further study that looked individually at signaling through the four EP receptors (Lone et al., 2021) also suggested PKC, CDKs, CK2, MAPKs, PI3K and Src as nodes involved in PGE₂ signaling and used kinase inhibitors to confirm these. Interestingly, it appeared that the relative contributions of these kinases varied somewhat between cell types and naturally also between the EP receptors. Two further phosphoproteomics studies (Giansanti et al., 2013; de Graaf et al., 2014) supported the implication of the PI3K/Akt signaling pathway in PGE₂ signaling and also identified a few other PGE₂-regulated kinases, including ROCK2 and MAPK1. Identifying these kinase nodes provides useful starting points for more targeted studies of PGE₂ signaling through its different receptors in different T cell types.

Signaling Networks Regulated by PGE₂

One of the challenges associated with large phosphoproteomics data sets is going beyond regulated nodes and pathways to visualize the complete and often complex signaling networks arising from a given stimulation (Needham et al., 2019). A major obstacle in this respect is the limited and somewhat skewed knowledge of kinase-substrate interactions, highlighted in a recent review (Needham et al., 2019). Here, the authors describe how the regulating kinase has only been identified for 5% of the phosphoproteome, and the top 20% of kinases are responsible for regulating 90% of those sites. More than 150 kinases have no assigned substrates. Consequently, mapping a set of regulated phosphosites onto a network of kinase-substrate interactions is naturally challenging. Some interesting new approaches are being used to address this question—in particular, CRISPR has been used to delete certain kinases in the genome, followed by phosphoproteomics to assess the effects on the phosphoproteome (Isobe et al., 2017, 2020).

The studies reviewed here have used different methods to achieve visualization of PGE₂ signaling networks. In one article centered on PKA signaling (Giansanti et al., 2013), a PKA network was visualized in Cytoscape by using the proteins identified as potential PKA substrates in the study, and expanding with protein-protein interactions derived from the STRING database and kinase-substrate interactions from PhosphoSitePlus. Another article (de Graaf et al., 2014) used a similar approach to arrive at predicted networks and complexes of predicted PKA and CK2 substrates. In addition, the authors manually constructed a basic PGE₂ signaling network using kinases and substrates seen to be regulated in their study and connecting these using information from UniProt and PhosphoSitePlus, as well as information about the temporal regulation of the kinases and substrates from their study (see Table 2). Such manual curation is feasible for relatively limited networks but is unrealistic for mapping entire phosphoproteomics data sets onto a potential network.

In our recent paper, we used a different approach to predict possible signaling networks based on the sites seen to be regulated by the four different PGE₂ receptors (Lone et al., 2021). In this approach, PHOSphorylation NETworks for Mass Spectrometry (PHONeMeS) (Terfve et al., 2015) was applied by combining phosphoproteomic data with a network

of directed protein-protein and kinase/phosphatase to substrate interactions representing prior knowledge. This resulted in network models for stimulation of one or multiple PGE₂ receptors simultaneously. This modeling approach provides a new way of constructing possible signaling networks for large phosphoproteomics data sets (Table 2). In this case, the modeled networks helped visualize the differences in signaling between the different EP receptors. From the modeled networks it also appeared that PGE₂ signaling in CD4 cells is relatively similar to that in CD8 cells, with the main difference being in the intensity of the signaling, not the overall layout of the signaling pathways. Naturally, we see evidence for the canonical G protein-dependent pathways, including PKA, PLC/PKC, and PI3K/Akt, but another major prediction from these models was that a large part of the PGE₂ signaling was modeled as going through G protein-independent pathways, such as β -arrestin.

Distinct PGE₂ Responses Across T Cell Subtypes

The PGE₂ phosphoproteomics studies in T cells were carried out either in the Jurkat T cell line (Giansanti et al., 2013; de Graaf et al., 2014) or in primary T cells (Oberprieler et al., 2010; Lone et al., 2021). Many features of PGE₂ signaling pathways, including kinase nodes and pathways involved, appear to be shared between the cell line and primary cells. The phosphosites regulated by PGE₂ also show significant overlap between studies in cell lines versus studies in primary cells (Fig. 2), where the Giansanti et al., and de Graaf et al. studies were carried out in the Jurkat cell line and the Lone et al. and Oberprieler et al. studies were performed in primary T cells. We note that there are also a number of phosphosites specific to each study, likely due to specific experimental or technical conditions in each experiment. For instance, de Graaf et al. and Lone et al. were label-free, whereas Giansanti et al. and Oberprieler et al. used stable isotope dimethyl labeling for quantitation, which could introduce some differences in what peptides were detected. In addition, Giansanti et al. differed from the other studies in that it used a PKA motif antibody for enrichment, which would also naturally have a large impact on which peptides were detected. Given the differences in methodological approaches and cell types investigated, it is unsurprising that the overlap between the studies is relatively modest.

Interestingly, there also appear to be certain differences in the signaling between primary T cell subtypes when directly compared against each other, underlining the complexity of PGE₂ signaling in T cells. In particular, the intensity and to some extent duration of signaling appears to be the

strongest in CD8+ cells and, in particular, in CD8 memory cells (Oberprieler et al., 2010; Lone et al., 2021). One study found that similar signaling pathways appear to be present in the different T cell subsets but that the intensity and also relative contributions of these pathways likely differs across cell types. For instance, CK2 appears to have a stronger contribution in CD4 than in CD8 cells (Lone et al., 2021), in line with literature on possible roles of CK2 in CD4 cells (Gibson and Benveniste, 2018). Studies in cell types beyond T cells have shown that PGE₂ signaling in other cell types also shares certain features with the signaling observed in T cells. For instance, a PGE₂ phosphoproteomics study in fibroblasts showed that PKA was a key node in the signaling network here, too, and that PGE₂ was involved in the regulation of many of the same cellular functions as in T cells—for instance, cytoskeletal structures (migration/motility), regulators of G protein-coupled receptor function, protein kinases, and transcriptional/translational regulators (Gerarduzzi et al., 2014; Lone et al., 2021). PGE₂ is thought to also play an important role in regulating the functions of a number of immune cells involved in cancer (Wang and DuBois, 2013), although so far the mechanisms behind these roles have not been studied with phosphoproteomics methods.

Temporal Patterns in PGE₂ Signaling

Several of the phosphoproteomics studies of PGE₂ signaling in T cells included multiple time points (Oberprieler et al., 2010; Giansanti et al., 2013; de Graaf et al., 2014), allowing information also on temporal aspects of this process and from a modeling perspective introducing directional edges when mapping signal networks (Fig. 3). In one study, 0-, 1-, and 60-minute time points were used to study the temporal regulation of potential PKA substrates by PGE₂ (Giansanti et al., 2013). Five distinct temporal profiles were identified, of which three showed upregulation over time, one showed no regulation, and one profile showed downregulation at the 1- and/or 60-minute time points. This downregulation of PKA substrate phosphorylation in response to PGE₂ stimulation in a small subset of regulated sites is counterintuitive, but it could be due to a postactivation phenomenon. In our recent study, a PKA-like motif was observed in many downregulated sites at the 10-minute time point, perhaps indicating a similar phenomenon at this time (Lone et al., 2021).

In another study, label-free quantitation allowed the monitoring of additional time points—namely, 0, 5, 10, 20, 30, and 60 minutes (de Graaf et al., 2014). The authors note that including these additional time points may be useful in identifying transiently activated substrates and enabled the




Fig. 2. Overlap in phosphorylation sites regulated in the four studies. Venn diagrams showing the overlap between the four phosphoproteomics studies of PGE₂ signaling in T cells. For the (Lone et al., 2021) study, all regulated sites, also from stimulation with individual EP agonists, were included. As evident from this illustration, some of the regulated sites are specific to each study, and some are shared between studies. Left panel does not include de Graaf et al. (2014), which was a targeted study of PKA substrates. Right panel includes all four studies described here.




Fig. 3. Schematic showing kinetics of phosphorylation for phosphosites at different relative positions in a phosphorylation cascade. Phosphorylation time courses may in some cases be used to infer the position of a phosphosite in a signaling pathway, with early phosphorylation suggesting a position near the top of a signaling cascade (red) and later phosphorylation suggesting a position further down in the cascade (blue).

grouping of sites according to temporal regulation patterns, with five clusters showing different upregulation patterns and three showing different downregulation patterns. Interestingly, different kinases appeared to be active at the different time points, as evidenced by distinct kinase predictions and regulated phosphorylation motifs in the different clusters and also introducing the possibility of signal amplification by serially activated kinases along the same pathway (Fig. 3). For instance, basic motifs were mostly upregulated at the early time points, such as 5 and 10 minutes, whereas acidic motifs were more enriched at 20 minutes and later, and proline-directed motifs did not show any particular temporal patterns. This is supported by kinase predictions, which indicate upregulation of basophilic kinases, for instance PKA and PKC, at early time points and acidophilic kinases, such as CK1 and CK2, at 20 minutes and later time points. In some cases, these temporal profiles could aid functional delineation and kinase function assignments (Fig. 3). For instance, CLK1 and CLK4 displayed a distinct temporal profile in this study, with activation at an intermediate time point, and for this temporal cluster, the term mRNA processing was highly enriched in Gene Ontology (GO) analysis, aligning well with what is known about CLK1 function in the mRNA spliceosomal complex. Interestingly, a greater number of phosphosites were regulated at later time points than at earlier time points in this study, suggesting amplification of the original signaling response and that kinases activated at later time points may thus constitute a broader, secondary response to PGE₂ (Fig. 3). On the other hand, some kinases may become inactive over time, leading to lower phosphorylation levels of the final substrate, such as in the case of S3 on CFL, which showed decreased abundance at late time points, likely due to inactivation of the intermediate nodes RhoA, ROCK, or LIMK.

A further study in primary T cells used the time points 0, 10, and 60 minutes and saw similar temporal patterns as above (Oberprieler et al., 2010), with most phosphosites clustering into groups with maximum phosphorylation at 10 or 60 minutes. This study had another unusual feature in that it combined mass spectrometry-based phosphoproteomics with phosphoflow to get both the global view from phosphoproteomics as well as a more high-throughput and detailed view from phosphoflow, including the ability to get detailed temporal information. The six phosphosites examined by phosphoflow exhibited distinct kinetics. A general

PKA substrate antibody showed maximum phosphorylation at 10 minutes and GSK3a pS21, a PKA substrate, had a similar temporal profile, agreeing with the results described above with early maximal activation for PKA (Giansanti et al., 2013; de Graaf et al., 2014). Of the other sites, some came up early (HSP27 pS78 at 3 minutes) or intermediate (S6 ribosomal protein pS235/236), and others came up late (Histone H3 pS10). Notably, for the phosphosites also seen by mass spectrometry, the temporal patterns were similar between the two techniques, confirming the usefulness of this combination of techniques to get more detailed temporal information in a high-throughput manner.

A more recent study of PGE₂ signaling also used the combined phosphoproteomics and phosphoflow cytometry approach to individually characterize PGE₂ signaling through each of its four receptors on T cells and how this differs between T cell subtypes (Lone et al., 2021). This study focused on a single early/intermediate time point, namely 5 minutes, and observed both basic, acidic, and proline-directed motifs at this time point. Kinases found in other studies to be primarily “early” or “late” were both predicted at this time point (de Graaf et al., 2014), indicating that at this intermediate time point, it may be possible to observe both the tail end of early signaling as well as the beginning of late-onset signaling events. The phosphoflow cytometry portion of this study confirmed a distribution of temporal profiles in PGE₂-regulated phosphorylation sites, with some phosphosites showing maximum regulation at early time points (e.g., vimentin pS38, VASP pS157), intermediate time points (e.g., S6RP pS240, NDRG1 pT346), or late time points (e.g., CREB pS133, histone H3 pS10, pS28). Interestingly, some of the proteins investigated had multiple phosphosites, and these were seen to be regulated with different dynamics—for instance, in the case of S240 and S235/236 on S6RP. Of the potential PKA substrates, a majority were early, including GSK3a pS21, VASP pS157, vimentin pS38, and HSP27 pS78, with a few showing later activation, including histone H3 pS10 and CREB pS133. The differing kinetics could be due to cellular localization or contributions from kinases beyond PKA that have different activation dynamics. This study was also able to highlight some of the difference between receptors and cell types when it comes to the dynamic signaling response to PGE₂. In particular, the EP₂ receptor signaled with stronger and more prolonged dynamics than the EP₄ receptor, which we hypothesize is due to a weaker functional coupling to cAMP and PKA as well as less rapid receptor internalization.

In addition, certain T cell subtypes, in particular CD8CD45RO, appeared to have stronger and more prolonged signaling responses than other cell subtypes.

Functional Output of PGE₂ Signaling in T Cells

One of the major current challenges in phosphoproteomics is translating information on regulated phosphosites into effects on cellular function (Needham et al., 2019). Although more than 200,000 phosphosites are currently known (Hornbeck et al., 2012), fewer than 3% of identified human phosphosites have a reported function (Needham et al., 2019). Several approaches can be used to identify or predict the functionality of particular phosphorylation sites, with one recent approach using machine learning to predict which phosphosites are likely to be functional (Ochoa et al., 2019). In the PGE₂ signaling studies in T cells, the function of individual phosphosites has largely been explored using either predictive software such as Predict Functional Phosphosites (PFP) (Xiao et al., 2016) or using GO analysis (Ashburner et al., 2000; Bindea et al., 2009; Carbon et al., 2019), for which function prediction is at the protein level. If a site is thought to be functionally important through bioinformatic analysis, small interfering RNA (siRNA) knockdown or CRISPR gene editing can be used to delete the phosphosite or replace it with a nonphosphorylatable amino acid or a phosphomimetic to further elucidate the functional role of the phosphosite in cells (Dukic et al., 2018; Aggarwal et al., 2019; Liu et al., 2020).

Through the four phosphoproteomics studies of PGE₂ signaling in T cells, a number of functional outputs of this signaling have been predicted or confirmed. In particular, the intersection of PGE₂ signaling with TCR signaling has been a theme in several of the studies. In one study, many proteins involved in TCR signaling, such as CARD11, PLCG1, WIPF1, GRAP2, NFATC2, FYB1, and NCK1, were found to be phosphorylated in response to PGE₂ (Oberprieler et al., 2010). In our more recent study, we observed that all four EP receptors regulate the phosphorylation of proteins contained in the GO term “TCR signaling pathway” and that stimulation with PGE₂ or a specific agonist of the EP₂ receptor gives enrichment of this GO term. TCR signaling proteins whose phosphorylation state was regulated by PGE₂ or EP₂ agonists include ARHGEF7, CARD11, CD247, FYB1, FYN, GRAP2, INPP5D, LAT, LCK, LCP2, LIME1, MAP3K7, NCK1, NCOR2, PAG1, PAK2, PDPK1, PIK3R1, PLCG1, PRKCQ, PSMA5, PSMD11, PSMD2, PSMD3, PTPN22, PTPRC, RFTN1, TESPA1 and WAS. A few proteins, namely GRAP2, PAG1, PLCG1, and PSMD3, were unique to PGE₂, whereas all other proteins regulated by PGE₂ were also found in the EP₂ agonist regulated protein set, suggesting that much of the PGE₂ signaling that intersects with TCR signaling goes via the EP₂ receptor. Interestingly, in this study, we observed regulation of the inhibitory Lck pY505 site only in CD4 cells, in which it was elevated in all conditions. This site has been shown to partake in an inhibitory PGE₂ pathway that intersects TCR signaling. This pathway is triggered by EP₂ or EP₄, and proceeds via cAMP-mediated PKA activation, which leads to Csk phosphorylation and inhibitory phosphorylation of Lck at Y505 (Vang et al., 2001; Ruppelt et al., 2007; Wehbi and Taskén, 2016).

A number of other functions were also predicted by GO analysis in our study, including cytoskeleton organization,

mRNA processing, cell-cell adhesion, cell polarity, and small GTPase-mediated signal transduction, which were enriched in all stimulation conditions in CD8 cells. Some of these functions appear to be conserved across cell types, as similar functions were also predicted in fibroblasts (Gerarduzzi et al., 2014). In terms of more specific immune functions, GO analysis showed enrichment for T cell activation (upon EP₁, EP₃, and PGE₂ stimulation), establishment of T cell polarity (EP₃, EP₄, PGE₂), thymic T cell selection/T cell differentiation in thymus (EP₁, EP₃, EP₄), lymphocyte migration (EP₄), and lymphocyte proliferation (EP₃), which is in line with some of the known functions of PGE₂ in T cells (Lone and Taskén, 2013).

In addition, one study (Lone et al., 2021) used the PFP algorithm to predict which regulated phosphosites were likely functional. Although there is some discussion about whether all phosphosites are in fact functional or whether some simply result from off-target effects of kinases (Lienhard, 2008), the PFP algorithm aims to identify the phosphosites most likely to have biologic functions based on conservation, kinase association, and structure information. In this study, PFP thus yielded a list of potentially biologically active phosphosites, as well as a number of possible functional outputs of PGE₂ signaling for those sites already annotated with biologic function. Conveniently, the study also provides information on cell types in which these phosphorylation events occur and the receptor stimulation conditions under which they are most likely to be regulated. This provides a very useful starting point for functional studies in T cells.

Manual assessment of the functional roles of individual sites by consulting the literature can also be an option if only looking at a limited number of sites, and this importantly provides crucial information compared with STRING or GO analysis, which do not have directionality. This is a limitation in terms of pathway and network modeling. To identify sites of particular importance, one strategy might be to consider the magnitude of the change in phosphorylation level in response to the stimulus and focus on changes that have a larger fold change or are more statistically significant. Another strategy might be to include temporal information to get directional information on edges (Fig. 3). However, manual curation is required in this process, as fold changes are influenced by many factors, including kinetics of phosphorylation, position in signaling pathway, cellular location, and turnover, and therefore fold change does not always correlate with more meaningful or functionally significant phosphorylation events. The PhosphoSitePlus database (Hornbeck et al., 2012) provides a reference for what is currently known about the function of specific phosphorylation events. Most of the sites monitored by phosphoflow in the two combined phosphoproteomics/phosphoflow cytometry studies are relatively well characterized in the literature and are also annotated in PhosphoSitePlus, and many of them have known biologic functions, for instance, in cytoskeletal function, T cell polarization, transcription, and translation, which aligns well with the GO analysis in the latter study (Lone et al., 2021). Another study (de Graaf et al., 2014) also found many of the same functions to be regulated by PGE₂. Here, manual inspection of phosphosites revealed some of the functional associations, such as S2152 on FLNA and S16 on STMN1, implying the intersection of PGE₂ signaling with cytoskeleton reorganization, and upregulation of pS118 in BAD, implying downregulation of apoptosis.

Also, gene ontology analysis was employed and showed the regulation of endocytosis, RNA processing, and DNA-related terms. Interestingly, these terms were upregulated in different temporal clusters of phosphosites, indicating regulation of different processes at different time points after PGE₂ stimulation, likely correlating with activation of different kinases at different time points. Using GO-based functional annotation of substrate interaction networks for the kinases CK2 and PKA, the paper found that the CK2-specific substrate interaction networks DNA repair and mRNA translation occurred only in the temporal clusters with delayed upregulation, matching CK2's observed late upregulation. Similarly, the PKA-specific substrate interaction network "T cell signaling" was found only in the temporal cluster of phosphosites that remained upregulated over time. Interestingly, another study found that PGE₂-triggered PKA substrates were involved in a number of other biologic processes as well, including transcription, translation, cytoskeletal function, kinase and phosphatase function, and more (Giansanti et al., 2013), illustrating how one kinase node in a signaling network can regulate many different biologic processes and underlining the key role of the PKA node in PGE₂ functional regulation.

The known functions of PGE₂ in T cells, including in differentiation, proliferation, apoptosis, and more (Lone and Taskén, 2013), align well with the biologic functions identified in these proteomics studies, for instance, cell cycle regulation, cytoskeletal remodeling, transcription, and translation and, in particular, the immunologic functions identified, such as T cell activation, establishment of T cell polarity, thymic T cell selection/T cell differentiation in thymus, lymphocyte migration, and lymphocyte proliferation.

Together, these functional interpretations have led to the strong implication of PGE₂ signaling in certain important cellular and immunologic processes, such as regulation of RNA- and DNA-related processes, cytoskeleton remodeling, T cell signaling, and more. Importantly, these studies have generated specific hypotheses that can then be tested based on evidence of PGE₂ involvement in specific processes. Furthermore, some of the studies have also provided more detailed information about the mechanisms and kinetics with which PGE₂ regulates this diverse biology, for instance through which receptors and kinases the functions may be regulated and with what temporal dynamics. One can envision that more directed functional studies can now be carried out on specific identified regulated phosphosites that, through these phosphoproteomics studies, have been strongly implicated in the regulation of specific processes by PGE₂.

Perspectives and Future Directions

The phosphoproteomics studies described here have significantly contributed toward an improved understanding of PGE₂ signaling in T cells. This includes insights into specific pathways triggered by the four PGE₂ receptors, which kinase nodes are active in these pathways, and how receptors and pathways crosstalk to form signaling networks upon PGE₂ stimulation. Thanks to temporal phosphoproteomics studies and complementary phosphoflow cytometry studies, we also have detailed information about the temporal regulation of many of the signaling pathways, as well as about differences in signaling between different T cell subtypes. Further, the

studies have suggested possible functional outcomes of PGE₂ stimulation in T cells. Together, they constitute a solid platform for targeted studies of specific PGE₂-triggered pathways in T cells and enable more directed functional studies for particular PGE₂-triggered pathways. These PGE₂ signaling studies further showcase some of the common current challenges and future directions of phosphoproteomics studies. In particular, they illustrate that the nature of the signaling response from a single given stimulus, in this case PGE₂, is not that of a single, linear pathway, but rather a complex, interconnected network that integrates multiple signals, in this case from multiple receptors and multiple kinase nodes (Needham et al., 2019). In this way, phosphoproteomics becomes a key tool in understanding the behavior of entire systems rather than individual, isolated pathways, and the temporal and quantitative nature of the technique is an important asset in understanding how these networks are regulated.

The studies also illustrate some of the current challenges in phosphoproteomics, including those in understanding the upstream regulation and downstream function of phosphosites (Needham et al., 2019). Progress in mapping more kinase-substrate interactions (Sugiyama et al., 2019), as well as in the development of software and modeling methods that allow the organization of phosphoproteomics data into predicted pathways and networks (Kotecha et al., 2010; Krämer et al., 2014; Raaijmakers et al., 2015; Terfve et al., 2015), will continue to contribute toward the successful interpretation of phosphoproteomics studies. As for the issue of predicting function based on specific regulated phosphosites, methods for predicting which phosphosites are functional are constantly improving (Beltrao et al., 2012; Xiao et al., 2016; Ochoa et al., 2019), and lists of phosphosites with known function are also continuously lengthening (Hornbeck et al., 2012). These advances will keep improving the translation of phosphoproteomics data into actionable functional predictions. There are also some challenges in phosphoproteomics specific to immune cells. For instance, depending on the particular cell type, the number of cells obtained can be quite low. For instance, Tregs may need to be expanded prior to analysis because of their relatively low abundance, which could alter the signaling properties of the cells (Lone et al., 2021). As the sensitivity of mass spectrometers keeps increasing, however, this will become less of a hurdle (Riley and Coon, 2016; Álvarez-Salamero et al., 2017; Needham et al., 2019).

We envision that future directions in phosphoproteomics studies of PGE₂ signaling in T cells may include further investigations of signaling differences between T cell subtypes. For instance, the advent of mass cytometry is facilitating the simultaneous observation of multiple phosphorylation events in ever-smaller subsets of cells (Gullaksen et al., 2019; Helou and Salomon, 2015), even within a single cell, thus facilitating a better understanding of heterogeneity in signaling responses between cells and between cell types. Single-cell mass spectrometry is also under development and may eventually include the possibility of looking for phosphorylation events in single cells (Marx, 2019; Specht et al., 2019). Similarly, as the sensitivity of mass spectrometry approaches keeps increasing and less material is required for analysis, it will also be possible to study signaling in smaller and smaller T cell subsets without necessitating cell expansion prior to analysis (Álvarez-Salamero et al., 2017). Interesting subsets to analyze for signaling differences might be subsets of helper

and cytotoxic T cells, such as Tregs, T helper 17 (Th17) cells, and others, to be able to correlate the differing functional effects of PGE₂ in these cell types, for instance, in T cell differentiation. It would also be interesting to study any changes in PGE₂ signaling in contexts with prolonged dysregulation of PGE₂, such as certain cancers and chronic inflammation, for instance, in cells that express exhaustion markers or have upregulated immune checkpoints. It would also be interesting to more comprehensively study how PGE₂ signaling differs in patients with cancer with upregulated versus normal PGE₂ levels (Moltu et al., 2017). In this and possibly other contexts, it would be a valuable extension from the current studies to also perform integrated phosphoproteomics/transcriptomics/proteomics studies, with the aim of correlating changes in phosphorylation patterns with later, possibly permanent changes in gene and protein expression levels. A few examples of such integrated studies on other topics are now available (Rotival et al., 2015; Gao et al., 2019; Zadora et al., 2019).

Another direction for PGE₂ signaling studies might be the comparison with other cell types beyond T cells to assess commonalities and differences in signaling and in functional outcome of the signaling in these cell types. Although PGE₂ signaling by phosphoproteomics has been mostly studied in T cells to date, one phosphoproteomics study in fibroblasts is available (Gerarduzzi et al., 2014), and many of the findings in this study echo the results in T cells. In particular, PKA has a key role in PGE₂ signaling networks in this cell type as well, and PGE₂ regulates functional processes such as cytoskeletal rearrangement, GPCR function, kinases, and transcription/translation, similar to what was found in T cells. At the same time, PGE₂ signaling in fibroblasts has a net functional output that is naturally distinct from that in T cells (namely, as an antifibrotic mediator), and this phosphoproteomic study gives new insight into molecular mechanisms for PGE₂ regulation of fibroblast activation and potential starting points for more targeted studies to elucidate these mechanisms. Interestingly, PGE₂ is known to have important and distinct functional roles in many other cell types, for instance, natural killer cells (Holt et al., 2011) and B cells (Murn et al., 2008), and it may be fruitful to use phosphoproteomic approaches to gain further insight into the molecular regulation of these functions. In addition, gene expression profiles for the different EP receptors indicates that their relative expression levels vary significantly between tissues (Consortium, 2013), so it would also be interesting to explore PGE₂ signaling by phosphoproteomics in other tissue types with differing relative receptor distribution patterns. Expanding the perspective, it would also be interesting to use phosphoproteomics to understand the signaling of other GPCR families that form signaling networks, for instance, the adrenergic receptor family, which also contains two Gα_s, one Gα_i, and one Gα_q receptor (Hall, 2004; Fujino and Regan, 2006). Exploring signaling in this or other GPCR signaling networks through phosphoproteomics would be a worthwhile community project.

Already, the results from the phosphoproteomics studies have been used as a basis for more targeted biochemical and functional studies (Burdyga et al., 2018; Moiseeva et al., 2019; Moltu et al., 2017), and this is also a possible direction for further research. The most recent phosphoproteomics study of PGE₂ signaling in T cells assessed the relative contributions of the four different EP receptors to PGE₂ signaling in subtypes

of T cells, as well as the overlap of these and the relative contributions of G protein-dependent and -independent signaling. It would be interesting to further characterize possible crosstalk and synergies between these receptors in molecular detail, for instance, using phosphoflow cytometry, and such studies would be aided by the ever-increasing repertoire of agonists and antagonists of the different receptors (Marković et al., 2017; Woodward et al., 2011). Through such molecular studies, one might also be able to assess the effect of different kinase inhibitors and/or disruptors of known PGE₂ signaling pathways (Stokka et al., 2009; Torheim et al., 2009) to see how this affects specific pathways as well as PGE₂ signaling more generally. Another direct continuation of these studies would be to test the predicted functional outcomes of PGE₂ signaling in more detail, for instance by using lists of PGE₂-regulated sites with known biologic function obtained from the phosphoproteomics studies and characterizing the mechanisms and pathways by which PGE₂ might regulate function through these sites. GO analyses from these phosphoproteomics studies could also be used as a basis for studies of the mechanisms behind how PGE₂ regulates specific T cell biologic functions. Although many of the current studies have focused on PKA as a major node in PGE₂ signaling, it would also be interesting to target other kinases identified as important, for instance, through targeted phosphoproteomics studies.

All in all, the phosphoproteomics studies carried out in the previous decade have provided a trove of information and insights into PGE₂ signaling pathways in T cells and we hope they will continue to spark new studies that further elucidate how PGE₂ signaling pathways and networks behave and may be targeted under normal and disease conditions.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Lone, Taskén.

References

- Aggarwal S, Gabrovsek L, Langeberg LK, Golkowski M, Ong SE, Smith FD, and Scott JD (2019) Depletion of dAKAP1-protein kinase A signaling islands from the outer mitochondrial membrane alters breast cancer cell metabolism and motility. *J Biol Chem* **294**:3152–3168.
- Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, and Mustelin T (2004) Protein tyrosine phosphatases in the human genome. *Cell* **117**:699–711.
- Álvarez-Salamero C, Castillo-González R, and Navarro MN (2017) Lighting up T lymphocyte signaling with quantitative phosphoproteomics. *Front Immunol* **8**:938.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al.; The Gene Ontology Consortium (2000) Gene ontology: tool for the unification of biology. *Nat Genet* **25**:25–29.
- Bains SJ, Mahic M, Myklebust TA, Småstuen MC, Yaqub S, Dørum LM, Bjørneth BA, Møller B, Brudvik KW, and Taskén K (2016) Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study. *J Clin Oncol* **34**:2501–2508.
- Bastepe M and Ashby B (1999) Identification of a region of the C-terminal domain involved in short-term desensitization of the prostaglandin EP4 receptor. *Br J Pharmacol* **126**:365–371.
- Beltejar MG, Lau HT, Golkowski MG, Ong SE, and Beavo JA (2017) Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells. *Proc Natl Acad Sci USA* **114**:E6240–E6249.
- Beltrao P, Albanese V, Kenner LR, Swaney DL, Burlingame A, Villén J, Lim WA, Fraser JS, Frydman J, and Krogan NJ (2012) Systematic functional prioritization of protein posttranslational modifications. *Cell* **150**:413–425.
- Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z, and Galon J (2009) ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **25**:1091–1093.
- Brudvik KW, Henjum K, Aandahl EM, Bjørneth BA, and Taskén K (2012) Regulatory T-cell-mediated inhibition of antitumor immune responses is associated with clinical outcome in patients with liver metastasis from colorectal cancer. *Cancer Immunol Immunother* **61**:1045–1053.
- Brudvik KW and Taskén K (2012) Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states. *Br J Pharmacol* **166**:411–419.

- Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, and DuBois RN (2006) Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. *Proc Natl Acad Sci USA* **103**:1492–1497.
- Burdzyga A, Surdo NC, Monterisi S, Di Benedetto G, Grisan F, Penna E, Pellegrini L, Zaccolo M, Bortolozzi M, Swietach P, et al. (2018) Phosphatases control PKA-dependent functional microdomains at the outer mitochondrial membrane. *Proc Natl Acad Sci USA* **115**:E6497–E6506.
- Carbon S, Douglass E, Dunn N, Good B, Harris NL, Lewis SE, Mungall CJ, Basu S, Chisholm RL, Dodson RJ, et al.; The Gene Ontology Consortium (2019) The gene ontology resource: 20 years and still GOing strong. *Nucleic Acids Res* **47**:D330–D338.
- Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Taskén K, and Scott JD (2006) Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. *J Biol Chem* **281**:21535–21545.
- Chapman JD, Goodlett DR, and Masselon CD (2014) Multiplexed and data-independent tandem mass spectrometry for global proteome profiling. *Mass Spectrom Rev* **33**:452–470.
- Chun KS, Lao HC, Trempus CS, Okada M, and Langenbach R (2009) The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. *Carcinogenesis* **30**:1620–1627.
- Cohen P (2000) The regulation of protein function by multisite phosphorylation—a 25 year update. *Trends Biochem Sci* **25**:596–601.
- Cohen P (2014) Immune diseases caused by mutations in kinases and components of the ubiquitin system. *Nat Immunol* **15**:521–529.
- Consortium GT; GTE Consortium (2013) The genotype-tissue expression (GTEx) project. *Nat Genet* **45**:580–585.
- de Graaf EL, Giansanti P, Altelaar AF, and Heck AJ (2014) Single-step enrichment by Ti4+–IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. *Mol Cell Proteomics* **13**:2426–2434.
- De Keijzer S, Meddens MB, Torensma R, and Cambi A (2013) The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle. *Int J Mol Sci* **14**:6542–6555.
- Desai S, April H, Nwaneshiudu C, and Ashby B (2000) Comparison of agonist-induced internalization of the human EP2 and EP4 prostaglandin receptors: role of the carboxyl terminus in EP4 receptor sequestration. *Mol Pharmacol* **58**:1279–1286.
- DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) Beta-arrestins and cell signaling. *Annu Rev Physiol* **69**:483–510.
- Dukic AR, Gerbaud P, Guibourdenche J, Thiede B, Taskén K, and Pidoux G (2018) Ezrin-anchored PKA phosphorylates serine 369 and 373 on connexin 43 to enhance gap junction assembly, communication, and cell fusion. *Biochem J* **475**:455–476.
- Fujino H and Regan JW (2006) EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. *Mol Pharmacol* **69**:5–10.
- Fujino H, West KA, and Regan JW (2002) Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. *J Biol Chem* **277**:2614–2619.
- Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, et al. (2019) Integrated proteomic characterization of HBV-related hepatocellular carcinoma. *Cell* **179**:561–577.e22.
- Gerarduzzi C, He Q, Antoniuq J, and Di Battista JA (2014) Quantitative phosphoproteomic analysis of signaling downstream of the prostaglandin e2/g-protein coupled receptor in human synovial fibroblasts: potential antifibrotic networks. *J Proteome Res* **13**:5262–5280.
- Giansanti P, Stokes MP, Silva JC, Scholten A, and Heck AJ (2013) Interrogating cAMP-dependent kinase signaling in Jurkat T cells via a protein kinase A targeted immune-precipitation phosphoproteomics approach. *Mol Cell Proteomics* **12**:3350–3359.
- Gibson SA and Benveniste EN (2018) Protein kinase CK2: an emerging regulator of immunity. *Trends Immunol* **39**:82–85.
- Grimsrud PA, Swaney DL, Wenger CD, Beauchene NA, and Coon JJ (2010) Phosphoproteomics for the masses. *ACS Chem Biol* **5**:105–119.
- Gullaksen SE, Bader L, Hellesøy M, Sulen A, Fagerholt OHE, Engen CB, Skavland J, Gjertsen BT, and Gavasso S (2019) Titrating complex mass cytometry panels. *Cytometry A* **95**:792–796.
- Hall RA (2004) Beta-adrenergic receptors and their interacting proteins. *Semin Cell Dev Biol* **15**:281–288.
- Helou YA and Salomon AR (2015) Protein networks and activation of lymphocytes. *Curr Opin Immunol* **33**:78–85.
- Holt D, Ma X, Kundu N, and Fulton A (2011) Prostaglandin E(2) (PGE(2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. *Cancer Immunol Immunother* **60**:1577–1586.
- Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, Latham V, and Sullivan M (2012) PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. *Nucleic Acids Res* **40**:D261–D270.
- Isobe K, Jung HJ, Yang CR, Claxton J, Sandoval P, Burg MB, Raghuram V, and Knepper MA (2017) Systems-level identification of PKA-dependent signaling in epithelial cells. *Proc Natl Acad Sci USA* **114**:E8875–E8884.
- Isobe K, Raghuram V, Krishnan L, Chou CL, Yang CR, and Knepper MA (2020) CRISPR-Cas9 phosphoproteomics identifies multiple noncanonical targets of myosin light chain kinase. *Am J Physiol Renal Physiol* **318**:F600–F616.
- Kim JI, Lakshminathan V, Frilot N, and Daaka Y (2010) Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalosome. *Mol Cancer Res* **8**:569–577.
- Kotecha N, Krutzik PO, and Irish JM (2010) Web-based analysis and publication of flow cytometry experiments. *Curr Protoc Cytom* **Chapter 10**:Unit10.17.
- Krämer A, Green J, Pollard J Jr, and Tugendreich S (2014) Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics* **30**:523–530.
- Lahiry P, Torkamani A, Schork NJ, and Hegele RA (2010) Kinase mutations in human disease: interpreting genotype-phenotype relationships. *Nat Rev Genet* **11**:60–74.
- Lemeer S and Heck AJ (2009) The phosphoproteomics data explosion. *Curr Opin Chem Biol* **13**:414–420.
- Lienhard GE (2008) Non-functional phosphorylations? *Trends Biochem Sci* **33**:351–352.
- Liu X, Xiao W, Zhang Y, Wiley SE, Zuo T, Zheng Y, Chen N, Wang X, Zheng Y, et al. (2020) Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function. *Proc Natl Acad Sci USA* **117**:328–336.
- Lone AM, Giansanti P, Jørgensen JM, Gjerga E, Dugourd A, Scholten A, Saez-Rodriguez J, Heck A, and Taskén K (2021) Systems approach reveals distinct, joint signaling networks of the four PGE₂ receptors in T cells. *Sci Signal* Submitted for publication.
- Lone AM and Taskén K (2013) Proinflammatory and immunoregulatory roles of eicosanoids in T cells. *Front Immunol* **4**:130.
- Luttrell LM and Miller WE (2013) Arrestins as regulators of kinases and phosphatases. *Prog Mol Biol Transl Sci* **118**:115–147.
- Macek B, Mann M, and Olsen JV (2009) Global and site-specific quantitative phosphoproteomics: principles and applications. *Annu Rev Pharmacol Toxicol* **49**:199–221.
- Mahic M, Yaqub S, Johansson CC, Taskén K, and Aandahl EM (2006) FOXP3+CD4+CD25+ adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. *J Immunol* **177**:246–254.
- Manning G, Whyte DB, Martinez R, Hunter T, and Sudarsanam S (2002) The protein kinase complement of the human genome. *Science* **298**:1912–1934.
- Marković T, Jakopin Ž, Dolenc MS, and Minarić-Rascan I (2017) Structural features of subtype-selective EP receptor modulators. *Drug Discov Today* **22**:57–71.
- Marx V (2019) A dream of single-cell proteomics. *Nat Methods* **16**:809–812.
- Mnatsakanyan R, Shema G, Basik M, Batist G, Borchers CH, Sickmann A, and Zahedi RP (2018) Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. *Expert Rev Proteomics* **15**:515–535.
- Moiseeva TN, Yin Y, Calderon MJ, Qian C, Schamus-Haynes S, Sugitani N, Osmanbeyoglu HU, Rothenberg E, Watkins SC, and Bakkenist CJ (2019) An ATR and CHK1 kinase signaling mechanism that limits origin firing during unperturbed DNA replication. *Proc Natl Acad Sci USA* **116**:13374–13383.
- Moltu K, Henjum K, Oberprieler NG, Bjørneth BA, and Taskén K (2017) Proximal signaling responses in peripheral T cells from colorectal cancer patients are affected by high concentrations of circulating prostaglandin E₂. *Hum Immunol* **78**:129–137.
- Mosenden R, Singh P, Cornez I, Heglid M, Ruppelt A, Moutschen M, Enerbäck S, Rahmouni S, and Taskén K (2011) Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. *J Immunol* **186**:5119–5130.
- Murn J, Alibert O, Wu N, Tendil S, and Gidrol X (2008) Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptgcr4. *J Exp Med* **205**:3091–3103.
- Nakanishi M and Rosenberg DW (2013) Multifaceted roles of PGE2 in inflammation and cancer. *Semin Immunopathol* **35**:123–137.
- Needham EJ, Parker BL, Burykin T, James DE, and Humphrey SJ (2019) Illuminating the dark phosphoproteome. *Sci Signal* **12**:eaau8645.
- Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, and Albelda SM (2016) Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. *Cancer Immunol Res* **4**:541–551.
- Nishigaki N, Negishi M, and Ichikawa A (1996) Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. *Mol Pharmacol* **50**:1031–1037.
- Nyman TA, Lorey MB, Cypryk W, and Matikainen S (2017) Mass spectrometry-based proteomic exploration of the human immune system: focus on the inflammasome, global protein secretion, and T cells. *Expert Rev Proteomics* **14**:395–407.
- O'Callaghan G and Houston A (2015) Prostaglandin E2 and the EP receptors in malignancy: possible therapeutic targets? *Br J Pharmacol* **172**:5239–5250.
- Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ, and Taskén K (2010) High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8+CD45RO+ T cells. *Blood* **116**:2253–2265.
- Oberprieler NG and Taskén K (2011) Analysing phosphorylation-based signalling networks by phospho flow cytometry. *Cell Signal* **23**:14–18.
- Ochoa D, Jarnuczak AF, Vieitez C, Gehre M, Soucheray M, Mateus A, Kleefeldt AA, Hill A, Garcia-Alonso L, Stein F, et al. (2019) The functional landscape of the human phosphoproteome. *Nat Biotechnol* **38**:365–373.
- Penn RB, Pascual RM, Kim YM, Mundell SJ, Krymskaya VP, Panettieri RA Jr, and Benovic JL (2001) Arrestin specificity for G protein-coupled receptors in human airway smooth muscle. *J Biol Chem* **276**:32648–32656.
- Raaijmakers LM, Giansanti P, Possik PA, Mueller J, Peepers DS, Heck AJ, and Altelaar AF (2015) PhosphoPath: visualization of phosphosite-centric dynamics in temporal molecular networks. *J Proteome Res* **14**:4332–4341.
- Riley NM and Coon JJ (2016) Phosphoproteomics in the age of rapid and deep proteome profiling. *Anal Chem* **88**:74–94.
- Rothwell PM, Wilson M, Elwin CE, Norving B, Algra A, Warlow CP, and Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. *Lancet* **376**:1741–1750.
- Rotival M, Ko JH, Srivastava PK, Kerločh A, Montoya A, Mauro C, Faull P, Cutillas PR, Petretto E, and Behmoaras J (2015) Integrating phosphoproteome and transcriptome reveals new determinants of macrophage multinucleation. *Mol Cell Proteomics* **14**:484–498.
- Ruppelt A, Mosenden R, Grönholm M, Aandahl EM, Tobin D, Carlson CR, Abrahamson H, Herberg FW, Carpen O, and Taskén K (2007) Inhibition of T cell

- activation by cyclic adenosine 5'-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. *J Immunol* **179**: 5159–5168.
- Scott JD, Dessauer CW, and Taskén K (2013) Creating order from chaos: cellular regulation by kinase anchoring. *Annu Rev Pharmacol Toxicol* **53**:187–210.
- Specht H, Emmott E, Petelski AA, Gray Huffman R, Perlman DH, Serra M, Kharchenko P, Koller A, and Slavov N (2019) Single-cell proteomic and transcriptomic analysis of macrophage heterogeneity using SCoPE2. *Genome Biol* **22**:50.
- Sreeramkumar V, Fresno M, and Cuesta N (2012) Prostaglandin E2 and T cells: friends or foes? *Immunol Cell Biol* **90**:579–586.
- Stokka AJ, Mosenden R, Ruppelt A, Lygren B, and Taskén K (2009) The adaptor protein EBP50 is important for localization of the protein kinase A-Ezrin complex in T-cells and the immunomodulating effect of cAMP. *Biochem J* **425**:381–388.
- Sugiyama N, Imamura H, and Ishihama Y (2019) Large-scale discovery of substrates of the human kinome. *Sci Rep* **9**:10503.
- Tan S, Chen X, Xu M, Huang X, Liu H, Jiang J, Lu Y, Peng X, and Wu B (2017) PGE₂/EP₄ receptor attenuated mucosal injury via β -arrestin1/Src/EGFR-mediated proliferation in portal hypertensive gastropathy. *Br J Pharmacol* **174**:848–866.
- Terfve CD, Wilkes EH, Casado P, Cutillas PR, and Saez-Rodriguez J (2015) Large-scale models of signal propagation in human cells derived from discovery phosphoproteomic data. *Nat Commun* **6**:8033.
- Tong D, Liu Q, Wang LA, Xie Q, Pang J, Huang Y, Wang L, Liu G, Zhang D, Lan W, et al. (2018) The roles of the COX2/PGE2/EP axis in therapeutic resistance. *Cancer Metastasis Rev* **37**:355–368.
- Torheim EA, Jarnaess E, Lygren B, and Taskén K (2009) Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. *Biochem J* **424**:69–78.
- Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skálhegg BS, Hansson V, Mustelin T, and Taskén K (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. *J Exp Med* **193**:497–507.
- von Stechow L, Francavilla C, and Olsen JV (2015) Recent findings and technological advances in phosphoproteomics for cells and tissues. *Expert Rev Proteomics* **12**:469–487.
- Walsh CT, Garneau-Tsodikova S, and Gatto GJ Jr (2005) Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem Int Ed Engl* **44**:7342–7372.
- Wang D and DuBois RN (2013) An inflammatory mediator, prostaglandin E2, in colorectal cancer. *Cancer J* **19**:502–510.
- Wang D and DuBois RN (2018) Role of prostanoids in gastrointestinal cancer. *J Clin Invest* **128**:2732–2742.
- Wehbi VL and Taskén K (2016) Molecular mechanisms for cAMP-mediated immunoregulation in T cells - role of anchored protein kinase A signaling units. *Front Immunol* **7**:222.
- Woodward DF, Jones RL, and Narumiya S (2011) International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. *Pharmacol Rev* **63**:471–538.
- Xiao Q, Miao B, Bi J, Wang Z, and Li Y (2016) Prioritizing functional phosphorylation sites based on multiple feature integration. *Sci Rep* **6**:24735.
- Yokoyama U, Iwatsubo K, Umemura M, Fujita T, and Ishikawa Y (2013) The prostanoid EP4 receptor and its signaling pathway. *Pharmacol Rev* **65**:1010–1052.
- Zadora PK, Chumduri C, Imami K, Berger H, Mi Y, Selbach M, Meyer TF, and Gurumurthy RK (2019) Integrated phosphoproteome and transcriptome analysis reveals chlamydia-induced epithelial-to-mesenchymal transition in host cells. *Cell Rep* **26**:1286–1302.e8.
- Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, et al. (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. *Cell* **162**:1257–1270.

Address correspondence to: Kjetil Taskén, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, P.O.Box 4953 Nydalen, N-0424 Oslo, Norway. E-mail: kjetil.tasken@medisin.uio.no
